Pursuits

Patients Get Extreme to Obtain Hepatitis Drug That's 1% the Cost Outside U.S.

Lock
This article is for subscribers only.

This is how far one Express Scripts Holding Co. executive was willing to go to secure inexpensive versions of Gilead Sciences Inc.’s hepatitis C drug Sovaldi, unavailable to U.S. consumers under federal drug import and patent laws.

His plan: Dock a cruise ship flying an Indian flag off the coast of Miami. Stock the ship with versions of Sovaldi sold in India for $83,000 less than the U.S. retail price for 12 weeks of treatment. Ferry U.S. patients to the boat and send them home with the potentially life-saving medicines at a huge discount.